Catalyst Pharmaceuticals Reports Growth Amid Generic Competition

Catalyst Pharmaceuticals (NASDAQ:CPRX) recently showcased significant growth within its rare disease portfolio, particularly for its lead product, Firdapse. During a discussion with Barclays life sciences analyst Glen Santangelo, Chief Executive Officer Rich Daly outlined the company’s strategies to enhance patient identification and market penetration. Additionally, Daly provided insights into the early commercial progress of Agamree, its treatment for Duchenne muscular dystrophy (DMD), and addressed the challenges posed by generic competition to Fycompa.

Firdapse and Agamree: Market Position and Future Plans

Catalyst is primarily focused on “ultra rare” conditions, offering three commercial products at various stages of their life cycles. In particular, Daly noted the potential for Firdapse, which has a revenue guidance of between $435 million and $450 million for 2026, representing an anticipated growth of 21% to 26%. Despite this optimistic outlook, Daly highlighted that market penetration remains low, especially in idiopathic LEMS, where misdiagnosis as generalized myasthenia gravis complicates patient identification.

Daly emphasized the importance of improving diagnostic practices through broader testing and adherence to updated care guidelines. He indicated that approximately 150 idiopathic patients could be diagnosed annually, alongside 900 cancer-associated30% for idiopathic LEMS and less than 10% for cancer-associated LEMS.

In terms of intellectual property, Catalyst has settled with two first filers, Lupin and Teva, establishing a January 2035 date for Teva. A trial involving the remaining litigant, Hetero, was scheduled to begin on March 23, 2024, though potential scheduling conflicts may affect this timeline.

Agamree’s Launch and Commercial Strategy

Daly reported a 68% increase in Agamree’s sales during the fourth quarter, driven by patients transitioning from generic prednisone and Emflaza. While there have been delays in switching some patients due to issues with the gene therapy Elevidys, Daly noted that Agamree has maintained strong performance. He pointed out that early steroid use in DMD can extend ambulation by approximately two to two-and-a-half years, making the need for effective treatment critical.

Catalyst has made headway in accessing treatment centers, with its commercial team achieving use in 100% of the top 45 centers that treat the majority of DMD patients. Daly also discussed ongoing clinical studies, including the SUMMIT trial, which aims to compare Agamree to standard care across various health metrics.

Regarding payer dynamics, both Firdapse and Agamree enjoy about 90% approval coverage, with no significant pushback reported from insurers.

Fycompa’s Challenges and Future Outlook

The entry of generics has impacted Fycompa, leading to a revised revenue guidance of $40 million to $45 million for 2026, down from a previous estimate of $115 million. Daly mentioned that promotional efforts have been scaled back to mainly online activities, while emphasizing the “sticky” nature of epilepsy treatment that can keep patients on therapy for extended periods.

Catalyst’s capital allocation strategy remains robust, with over $700 million in cash and no funded debt. The company is actively considering acquisitions, particularly targeting differentiated rare disease products with a peak revenue potential of around $500 million. A $200 million share repurchase authorization is also in place, running through December 2026, allowing flexibility in business development.

Daly projected an overall revenue guidance of between $615 million and $645 million for 2026, attributing slower growth primarily to Fycompa’s decline, while maintaining expectations for continued growth from Firdapse and Agamree.

Catalyst Pharmaceuticals remains committed to improving treatment options for patients with rare diseases, underscoring its dedication to addressing unmet medical needs in small patient populations.